Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of Tuspetinib (HM43239) in patients with relapsed or re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts-2
• Myelomonocytic Leukemia

Drugs mentioned

• Tuspetinib (HM43239)

Snippet

Sponsor: Aptose Biosciences Inc. | Conditions: Leukemia, Myeloid, Acute, Refractory AML | Phase 1, Phase 2 | Status: RECRUITING